Men whose infertility has a genetic cause sometimes face a decision their grandfathers never had to make: choose which embryos to transfer during IVF, and which to leave behind. Preimplantation genetic diagnosis, usually called PGD or PGT, screens IVF embryos for genetic conditions before implantation. When male-factor infertility is the reason, the condition often traces back to the man's Y chromosome, a CFTR mutation, or a chromosomal rearrangement. The ethical questions this raises are real, and most men walk into them unprepared for how heavy they feel.
This post is not a moral ruling. It is a map of the debates, drawn from the bioethics literature and the clinical guidelines that now shape this field. You should talk to a doctor or genetic counselor about your specific situation before making any decision.
What PGD actually does and when it comes up for male infertility
PGD works by removing a few cells from an embryo created in a lab, testing those cells for a specific genetic condition, and using the results to decide which embryos to transfer. The procedure is used when a couple has a known genetic risk. For male-factor infertility, that risk can come from a few places.
Y chromosome microdeletions are found in roughly 5 to 10 percent of men with severe low sperm counts and in a higher proportion of men with no sperm in the ejaculate. The deletions affect regions of the Y chromosome called AZF regions, which carry genes needed for sperm production. If a man with a Y microdeletion conceives via ICSI (a technique where a single sperm is injected into an egg), any son he has will inherit the same deletion and likely face the same fertility struggles. Some couples consider PGD to select female embryos, who cannot carry a Y chromosome deletion. That choice sits at the center of one of the most contested debates in reproductive ethics.
CFTR mutations are another route. Men with congenital bilateral absence of the vas deferens, a condition where the tubes that carry sperm do not form, often carry mutations in the CFTR gene even if they do not have full cystic fibrosis. If the female partner also carries a CFTR mutation, PGD can screen for the combination. Chromosomal rearrangements, such as balanced translocations, also lead some men to PGD after repeated pregnancy loss.
The procedure itself raises no new debate. What raises debate is what happens next.
The ethics of discarding embryos
PGD requires creating more embryos than will be transferred. Some will carry the genetic condition. Some may have chromosomal abnormalities. Some will be unaffected. The unaffected ones are typically transferred or frozen. The affected ones may be discarded, donated to research, or stored indefinitely.
For many people, the moral weight of this process depends on what they believe an embryo is. Some traditions hold that an embryo has full moral status from fertilization. For those who hold that view, discarding an embryo, any embryo, is a serious moral loss, and the fact that the embryo carries a genetic condition does not change that. Others hold that moral status develops gradually, or that early embryos do not yet have the capacities that ground moral protection. That view makes discarding embryos less morally troubling, though many who hold it still feel the weight of the decision.
Bioethicists who work in this field tend to focus less on abstract status and more on the reasons people give for discarding one embryo over another. A 2001 paper by philosopher Julian Savulescu in the journal Bioethics argued for a principle he called procreative beneficence: parents should choose the embryo, from the ones available, that has the best chance of the best life. On that framing, selecting against a genetic condition is justified because the condition would likely reduce the child's well-being. The HFE Act in the United Kingdom and the Human Fertilisation and Embryology Authority, the regulator it created, license PGD for conditions judged sufficiently serious by an independent committee.
The questions people ask here are specific. Is severe male infertility a serious enough condition to justify embryo selection? Does it matter that the condition affects reproductive options later in life rather than causing illness or early death? Different people answer differently, and the law in most countries does not give a single answer.
The disability rights critique
One of the strongest objections to PGD comes from disability scholars and advocates, not from religious groups. In 1999, bioethicist Adrienne Asch published a paper in the American Journal of Public Health arguing that prenatal and preimplantation testing for disability sends a message about who is welcome in society. Asch did not object to testing for conditions that cause early death or severe pain. She objected to testing for conditions, including some genetic conditions, where a person can live a good life with the condition.
Asch's core claim was that parents often reject embryos or fetuses with a condition based not on what life with that condition is actually like, but on fear, stigma, and a lack of contact with people who live with the condition. Her coauthored work with Erik Parens in a 1999 Hastings Center Report special issue laid out the disability rights critique of prenatal genetic testing in full. The argument applies to PGD just as much as to prenatal diagnosis.
For male infertility specifically, the critique has a particular edge. A Y chromosome microdeletion does not cause disease in the usual sense. A man with a Y microdeletion is healthy. He may need IVF with ICSI to conceive. He will not need dialysis or a wheelchair. He may live a full life and, with assisted reproduction, have his own children. Selecting female embryos to avoid passing on that microdeletion, from the disability rights perspective, treats a manageable difference as a reason to exclude someone from existence. That argument has forced even supportive clinicians to articulate why, if selecting against infertility is allowed, selecting against other traits is not.
The counterargument, put forward by Savulescu and others, is that fertility is a significant good, and that parents who can choose to give their child the option of natural conception, which a son with a Y microdeletion would not have, should be allowed to do so. Neither side has won the academic debate, and the disagreement shows up in policy. Some countries restrict PGD for conditions that are not life-threatening. Others leave it to clinics and parents.
Sex selection and the Y microdeletion scenario
PGD can reveal embryo sex because chromosomes are part of the test. For couples selecting against a Y chromosome microdeletion, sex selection is the mechanism. They have to select female embryos because male embryos carry the Y chromosome with the deletion. That is medical sex selection, meaning sex selection to avoid a sex-linked condition, not family balancing.
Medical sex selection for sex-linked conditions is widely permitted. Non-medical sex selection, choosing a child's sex for preference, is banned in the United Kingdom, prohibited by most professional guidelines in Australia and Europe, and unregulated in the United States. The debate around using sex selection to avoid male infertility is whether infertility counts as a medical reason strong enough to justify it. In 2013, an ESHRE Task Force on Ethics and Law published guidance in Human Reproduction on sex selection for non-medical reasons, arguing that the practice reinforces gender stereotypes and should not be offered. For medical sex selection, including selection against Y-linked conditions, the guidance was more permissive but still required clear justification.
A man who carries a Y microdeletion may feel a particular weight here. His own fertility struggle becomes the reason a clinic might recommend selecting not to have sons. Some men describe that as a relief, a way to spare a future son the same path. Others describe it as grief, or as a judgment on their own worth. Both responses are documented in the qualitative research on couples undergoing PGD for genetic conditions.
Access, cost, and who gets to choose
PGD is expensive. IVF alone costs tens of thousands of dollars in the United States per cycle, and PGD adds several thousand more. In countries with public funding, access depends on eligibility criteria and waiting lists. In the United States, access depends on insurance coverage, which is inconsistent for infertility care, and on personal wealth.
This creates a distributive justice problem. The ethical debates about embryo selection and disability rights assume that the choice to use PGD is available. For many men with genetic causes of infertility, it is not. Some bioethicists argue this matters as much as any abstract debate about moral status. A technology that is ethically contested but only available to wealthy families raises a different set of questions: who is this technology for, and whose values shape how it is used?
Israel is a notable outlier. The Israeli public health system funds IVF generously, and reproductive technology is widely accepted across religious and secular communities. PGD is more accessible there than almost anywhere else. The result is a natural experiment in what happens when cost is not the barrier. The uptake is high, but the ethical debates persist.
Informed consent and what PGD cannot detect
PGD has hard technical limits. It tests for the specific condition or chromosomal arrangement that the couple is at risk for. It does not test "for everything." PGT-A, which screens for chromosomal copy number, is a broader test, but it also has limits. It cannot detect many genetic conditions. It cannot detect environmental exposures, epigenetic effects, or the thousands of gene variants that shape complex conditions like asthma or schizophrenia.
The American Society for Reproductive Medicine and ESHRE both publish patient education materials that emphasize this. A 2024 review of patient understanding found that many couples overestimate what PGD can do. The risk is that parents choose embryos based on a test that gives less information than they think it does.
A newer development, PGT-P (polygenic), screens embryos for risk scores for common diseases like diabetes or heart disease. This is emerging research, not established practice, and most professional organizations, including ESHRE and ASRM, have cautioned against clinical use because the predictive value is unproven. Some clinics in the United States offer it anyway. The gap between what the science supports and what clinics market is something men should understand before consenting to any test.
Surplus embryos and the male partner's role
IVF creates surplus embryos. PGD does too. After the unaffected embryos are transferred or frozen, couples must decide what to do with the rest. Freeze them indefinitely, donate them to another couple, donate them to research, or discard them. Each option has its own ethical weight, and the decision often falls disproportionately on the female partner because her body is the one undergoing IVF. In male-factor infertility, though, the genetic reason for the testing originated with the man. That reversal can create tension.
Some men report feeling sidelined in the PGD process. The female partner undergoes egg retrieval, embryo transfer, and the physical burden of IVF. The male partner provides a sperm sample and genetic information. When the genetic condition is on his side, the ethical weight of having passed it on, even without knowing, can feel heavy. Research on couples undergoing PGD for genetic conditions, including male-factor conditions, documents guilt, blame, and the need for counseling that addresses both partners. Clinics that offer PGD are generally expected by professional guidelines to provide genetic counseling before the procedure, and psychosocial counseling is increasingly recommended.
Regulatory differences, briefly
The legal landscape varies so much that a couple's options depend heavily on where they live. In the United Kingdom, the HFEA licenses PGD condition by condition. A committee reviews whether the condition is sufficiently serious. In Australia, the National Health and Medical Research Council issues ethical guidelines that restrict PGD to serious conditions and require genetic counseling. In the United States, there is no federal regulation of PGD specifically. Professional guidelines exist but are voluntary, and clinics have wide discretion. Some states have religiously influenced restrictions on embryo research or disposal, which shape what clinics can offer.
This matters for men considering PGD because the ethical standards applied, and the conditions of access, are not uniform. A clinic in one country may refuse to offer PGD for Y chromosome microdeletions because it views male infertility as not serious enough to justify embryo selection. A clinic in another country may offer it without restriction. Understanding which framework a clinic operates under is part of informed consent.
Questions to ask a clinic or genetic counselor
Several questions come up repeatedly in the bioethics literature and in professional guidance. They are worth taking to any clinic visit:
- What exactly does the test detect, and what does it not detect?
- Is PGD for this condition permitted or restricted under the relevant regulatory framework?
- Does the clinic have a specific policy on sex selection for Y chromosome microdeletions?
- What happens to embryos that are not transferred?
- Does the clinic recommend PGT-A alongside PGD, and what is the evidence that PGT-A improves live birth rates for this specific condition?
- Who will provide genetic counseling, and is psychosocial counseling available for both partners?
- What does the clinic charge, and what is not covered by the quoted price?
These questions do not resolve the ethical debates. They do make the decisions clearer. Most of the moral weight in PGD comes from choices made under uncertainty. The better the information, the less avoidable regret.
The ethical debates around PGD for male infertility are not settled. They combine questions about the moral status of embryos, the message we send about disability, the limits of sex selection, the justice of access, and the accuracy of the tests themselves. A man who understands those debates will make a decision he can live with, whatever that decision is.
This content is for educational purposes only and is not medical advice. Oakman products are designed for physical comfort and cooling; they make no claims about fertility, sperm quality, or hormone levels. Consult a healthcare professional for personalized advice.